Melisa Wong Points Out Potential Age Bias in Active Treatment of Lung Cancer
Melisa Wong lays out the findings of a study she did looking at the age of patients with recurrent lung cancer and the likelihood they were to receive active treatment.
Melisa Wong on Factors That Affect Lung Cancer Treatment
Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology, Aging Research T32 Fellow, University of California San Francisco Geriatrics, discusses the impact that comorbidities have on the treatment for lung cancer.
Melisa Wong on Age Disparities in Treatment for NSCLC Recurrence
Melisa Wong, MD, Oncology Chief Fellow, Hematology/Oncology at the University of California San Francisco, discusses differences among age groups in the treatment of non–small cell lung cancer (NSCLC).
ASCO 2016: Melisa Wong Discusses Treatment of NSCLC Recurrence
Melisa Wong, MD, discusses an analysis of age and comorbidity on treatment of non-small cell lung cancer recurrence. Wong presented this analysis at the 2016 ASCO Annual Meeting.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
2 Clarke Drive Cranbury, NJ 08512